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A. B. G. and H. Overall survival and breast cancer-specific survival of stage IV patients with HER2+/HoR+ or HER2-/HoR-subtype had no differences according to site of distant metastasis (P > 0.05). C. D. E. and F. Overall survival and breast cancer-specific survival of stage IV patients with HER2-/HoR+ or HER2+/HoR-subtype had significant differences according to site of distant metastasis (P < 0.05).
Supplementary Figure S3
Supplementary Figure S3 . A. C. E. and G. Overall survival of stage IV patients with different molecular subtypes according to situation of primary tumor surgery (P < 0.001). B. D. F. and H. Breast cancer-specific survival of stage IV patients with different molecular subtypes according to situation of primary tumor surgery (P < 0.001). 
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